Asset
FILGOTINIB HYDROCHLORIDE
Lakefront Biotherapeutics American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01798979 | phase1 | completed | 2013-02-01 | 2013-04-01 | Lakefront Biotherapeutics NV | A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy Subjects |
| NCT01894516 | phase2 | completed | 2013-10-08 | 2015-03-05 | Lakefront Biotherapeutics NV | Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2) |
| NCT01888874 | phase2 | completed | 2013-07-17 | 2015-02-18 | Lakefront Biotherapeutics NV | Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1) |
| NCT01668641 | phase2 | completed | 2012-05-01 | 2012-09-01 | Lakefront Biotherapeutics NV | Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients |
| NCT02048618 | phase2 | completed | 2014-02-01 | 2015-11-01 | Lakefront Biotherapeutics NV | Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease |
FDA applications (0)
This company has no applications containing this asset.